So they published the results of one patient in th

Quote:

---

So they published the results of one patient in the New England Journal of Medicine and presented the outcomes of all three patients, including Ludwig, at a cancer conference anyway. From there, the money poured in.

---

Read More: https://investorshangout.com/post/view?id=557...z63Tu0PIFM

I thought that was interesting because maybe something Cydy could do if the results are good. They have two patients now and should have CTCs. The ctc testing I feel might be the best thing gotten with RP, even if the other stuff doesn’t work out, this should give an advantage getting leronlimab approved first compared to the other three BPs working with Ccr5 and cancer. BMS is the furthest alone with a couple years of data, which must be good since they added the drug in another trial I posted, but the ctc technology cuts the time to prove the drug is working down significantly. Then the safety issues, with leronlimab used in over 800 patients, with no serious adverse events, that gives leonlimab an advantage over the other drugs.